Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIR4156 plus semaglutide in adults with obesity
ACTRN12626001033336Phase 2Recruiting
- Sponsor
- Sironax
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SIR4156, semaglutide in obesity, sponsored by Sironax. Started May 2026; status: recruiting.
02
Drugs
SIR4156semaglutide
03
Conditions
obesity
Beyond the preview
Go deeper on ACTRN12626001033336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001033336.